Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25

Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25

Abstract Background Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an aggressive subtype, accounting for around 20% of all breast cancers. The development of HER2-targeted therapy has substantially improved patient outcomes. Nevertheless, the increasing rate of side effect...

Full description

Bibliographic Details
Main Authors: Yanjie Peng, Zhengli Wu, Zheng Pang, Lin Zhang, Dandan Song, Fang Liu, Yanhong Li, Tongjun Lin
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Microbial Cell Factories
Subjects:
Prokaryotic expression
Immunotoxin
HER2
Breast cancer
Manufacture
Evaluation
Online Access:https://doi.org/10.1186/s12934-023-02115-0

Internet

https://doi.org/10.1186/s12934-023-02115-0

Similar Items